Biology Reference
In-Depth Information
Liu Y, Fong M, Cone J, Wang S, Yoshitake M, Kambayashi J (2000) Inhibition of adenosine
uptake and augmentation of ischemia-induced increase of interstitial adenosine by cilostazol,
an agent to treat intermittent claudication. J Cardiovasc Pharmacol 36:351-360
Liu Y, Shakur Y, Yoshitake M, Kambayashi JJ (2001) Cilostazol (pletal): a dual inhibitor of cyclic
nucleotide phosphodiesterase type 3 and adenosine uptake. Cardiovasc Drug Rev 19:369-386
Loscalzo J (2001) Nitric oxide insufficiency, platelet activation, and arterial thrombosis. Circ Res
88:756-762
Madamanchi NR, Vendrov A, Runge MS (2005) Oxidative stress and vascular disease.
Arterioscler Thromb Vasc Biol 25:29-38
Manickavasagam S, Ye Y, Lin Y, Perez-Polo RJ, Huang MH, Lui CY, Hughes MG, McAdoo DJ,
Uretsky BF, Birnbaum Y (2007) The cardioprotective effect of a statin and cilostazol combi-
nation: relationship to Akt and endothelial nitric oxide synthase activation. Cardiovasc Drugs
Ther 21:321-330
Maurice DH (2005) Cyclic nucleotide phosphodiesterase-mediated integration of cGMP and
cAMP signaling in cells of the cardiovascular system. Front Biosci 10:1221-1228
Maurice DH, Palmer D, Tilley DG, Dunkerley HA, Netherton SJ, Raymond DR, Elbatarny HS,
Jimmo SL (2003) Cyclic nucleotide phosphodiesterase activity, expression, and targeting in
cells of the cardiovascular system. Mol Pharmacol 64:533-546
Mishima Y, Kuyama A, Ando M, Kibata M, Ishioka T (2000) Effects of cilostazol on serum
lipoprotein concentrations and particle size of low-density lipoproteins in patients with dysli-
pidemic NIDDM. J Jpn Atheroscler Soc 27:17-22
Mizutani M, Okuda Y, Yamashita K (1996) Effect of cilostazol on the production of platelet-
derived growth factor in cultured human vascular endothelial cells. Biochem Mol Med
57:156-158
Moher D, Pham B, Ausejo M, Saenz A, Hood S, Barber GG (2000) Pharmacological management
of intermittent claudication: a meta-analysis of randomised trials. Drugs 59:1057-1070
Mohler ER III, Beebe HG, Salles-Cuhna S, Zimet R, Zhang P, Heckman J, Forbes WP (2001)
Effects of cilostazol on resting ankle pressures and exercise-induced ischemia in patients with
intermittent claudication. Vasc Med 6:151-156
Mohler ER III, Hiatt WR, Creager MA (2003a) Cholesterol reduction with atorvastatin improves
walking distance in patients with peripheral arterial disease. Circulation 108:1481-1486
Mohler ER III, Hiatt WR, Olin JW, Wade M, Jeffs R, Hirsch AT (2003b) Treatment of intermittent
claudication with beraprost sodium, an orally active prostaglandin I2 analogue: a double-
blinded, randomized, controlled trial. J Am Coll Cardiol 41:1679-1686
Mondillo S, Ballo P, Barbati R, Guerrini F, Ammaturo T, Agricola E, Pastore M, Borrello F,
Belcastro M, Picchi A, Nami R (2003) Effects of simvastatin on walking performance and
symptoms of intermittent claudication in hypercholesterolemic patients with peripheral vascu-
lar disease. Am J Med 114:359-364
Morelli A, Filippi S, Mancina R, Luconi M, Vignozzi L, Marini M, Orlando C, Vannelli GB,
Aversa A, Natali A, Forti G, Giorgi M, Jannini EA, Ledda F, Maggi M (2004) Androgens
regulate phosphodiesterase type 5 expression and functional activity in corpora cavernosa.
Endocrinology 145:2253-2263
Mori D, Ishii H, Kojima C, Nitta N, Nakajima K, Yoshida M (2007) Cilostazol inhibits monocytic
cell adhesion to vascular endothelium via upregulation of cAMP. J Atheroscler Thromb
14:213-218
Movsesian MA (2002) PDE3 cyclic nucleotide phosphodiesterases and the compartmentation of
cyclic nucleotide-mediated signalling in cardiac myocytes. Basic Res Cardiol 97(Suppl 1):
I83-I90
Movsesian MA, Kukreja RC (2011) Phosphodiesterase inhibition in heart failure. In: Francis SH,
Conti M, Houslay MD (eds) Phosphodiesterases as drug targets. Springer, Heidelberg
Muller-Buhl U, Diehm C, Krais T, Zimmermann R, Morl H, Eckstein HH (1987) Clinical effects
of intravenous iloprost in patients with intermittent claudication. Eur J Clin Pharmacol
33:127-131
